Progenipoietins: Biological characterization of a family of dual agonists of fetal liver tyrosine kinase-3 and the granulocyte colony-stimulating factor receptor

Experimental Hematology

Volumn 29, Issue 1, 2001, Pages 41-50

  Streeter, Philip R ^a   Minster, Nancy I ^a   Kahn, Larry E ^a   Hood, William F ^a   Vickery, Lillian E ^a   Thurman, Tammy L ^a   Monahan, Joseph B ^a   Welply, Joseph K ^a   McKearn, John P ^a   Woulfe, Susan L ^a  

^a PFIZER INC   (United States)

Author keywords

Dendritic cells; Fetal liver tyrosine kinase 3 ligand; Granulocyte colony stimulating factor; Hematopoietic growth factors; Progenipoietin

Indexed keywords

GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; PROGENIPOIETIN; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ARTICLE; CELL PROLIFERATION; COLONY FORMING UNIT; DENDRITIC CELL; FLOW CYTOMETRY; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; LEUKOCYTE; NEUTROPHIL; PRIORITY JOURNAL; RECEPTOR BINDING;

AMINO ACID SEQUENCE; ANIMALS; BLOOD CELL COUNT; CELL DIVISION; CELL LINEAGE; COLONY-FORMING UNITS ASSAY; DENDRITIC CELLS; DRUG EVALUATION, PRECLINICAL; DRUG SYNERGISM; FEMALE; FMS-LIKE TYROSINE KINASE 3; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIESIS; HEMATOPOIETIC STEM CELLS; HUMANS; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTORS, GRANULOCYTE COLONY-STIMULATING FACTOR; RECOMBINANT FUSION PROTEINS;

TRIXIS;

EID: 0035166228     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0301-472X(00)00616-0     Document Type: Article

References (33)

1. Review; Stratton Lecture 1990. Clinical implications of positive and negative hematopoietic stem cell regulators
2. Differentiation and proliferation of hematopoietic stem cells
3. Hematopoietic regulators; redundancy or subtlety?
4. Human FLT3/FLK2 gene; cDNA cloning and expression in hematopoietic cells
5. Cellular and molecular characterization of the role of the FLK-2/FLT-3 receptor tyrosine kinase in hematopoietic stem cells
6. Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor; a proliferative factor for primitive hematopoietic cells
7. Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs
8. The FLT3 ligand potently and directly stimulates the growth and expansion of primitive murine bone marrow progenitor cells in vitro; synergistic interactions with interleukin (IL)-11, IL-12, and other hematopoietic growth factors
9. flk2/flt3 ligand is a potent cofactor for the growth of primitive B cell progenitors
10. Synergistic effect of FLT-3 ligand on the granulocyte colony-stimulating factor-induced mobilization of hematopoietic stem cells and progenitor cells into blood in mice
11. In vivo effects of Flt3/Flk2 ligand on mobilization of hematopoietic progenitors in primates and potent synergistic enhancement with granulocyte colony-stimulating factor
12. Synergy of growth factors during mobilization of peripheral blood precursor cells with recombinant human Flt3-ligand and granulocyte colony-stimulating factor in rabbits
13. Flt-3 ligand synergizes with granulocyte colony-stimulating factor to increase neutrophil numbers and to mobilize peripheral blood stem cells with long-term repopulating potential
14. Circular permutation of granulocyte colony-stimulating factor
15. Circular permutation of the granulocyte colony-stimulating factor receptor agonist domain of myelopoietin
16. Hematologic effects of flt3 ligand in vivo in mice
17. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice; multiple dendritic cell subpopulations identified
18. FLT3 ligand induces the generation of functionally active dendritic cells in mice
19. Flt3 ligand synergizes with granulocyte-macrophage colony-stimulating factor to mobilize hematopoietic progenitor cells into the peripheral blood of mice
20. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity
21. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity
22. DNA-based immunization by in vivo transfection of dendritic cells
23. Therapy of murine tumors with tumor peptide-pulsed dendritic cells; dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines
24. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts
25. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
26. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
27. Presentation of prostate tumor antigens by dendritic cells stimulates T-cell proliferation and cytotoxicity
28. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
29. Generation of immunostimulatory dendritic cells from human CD34+ hematopoietic progenitor cells of the bone marrow and peripheral blood
30. Progenitor recruitment and in vitro expansion of immunostimulatory dendritic cells from human CD34+ bone marrow cells by c-kit-ligand, GM-CSF, and TNF-α
31. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and downregulated by tumor necrosis factor-α
32. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells
33. Human CD14+ leukocytes acquire the phenotype and function of antigen-presenting dendritic cells when cultured in GM-CSF and IL-4